Sirius Collaborates with Parisian Hospitals | GenomeWeb

NEW YORK (GenomeWeb News) – Sirius Genomics will work with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic markers for severe sepsis under a collaborative agreement, the company said today.

Sirius will work with the hospital system's Clinical Research and Development Department in a program aimed at developing a pharmacogenomic diagnostic to assess the responsiveness of severe sepsis patients to recombinant human activated Protein C, which is sold by Eli Lilly under the trade name Xigris.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.